



Novo Nordisk – Shortage of Wegovy® (semaglutide)

- OptumRx has learned of a supply disruption of [Novo Nordisk's Wegovy \(semaglutide\)](#) 0.25 mg, 0.5 mg and 1 mg strengths until the 2nd half of 2022 due to manufacturing delays. The 1.7 mg and 2.4 mg dose strengths are expected to experience minimal disruption.
 - The Wegovy supply disruption is NOT due to a recall or safety-related issue.
 - The manufacturer Novo Nordisk uses to fill Wegovy pens has temporarily stopped manufacturing and deliveries due to manufacturing issues.
 - The supply disruption only impacts Wegovy and does not affect other Novo Nordisk products including Ozempic® (semaglutide).
- Wegovy is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m² or greater or 27 kg/m² in the presence of at least one weight-related comorbid condition [e.g. hypertension, type 2 diabetes mellitus (T2DM), or dyslipidemia].
 - The dose of Wegovy is initiated at 0.25 mg and titrated up to the 2.4 mg maintenance dose over a course of several weeks to minimize gastrointestinal adverse reactions.
- The 1.7 mg and 2.4 mg dose strengths are currently available; however, local pharmacies may continue to experience delays when ordering the 1.7 mg or 2.4 mg strengths. Patients recently prescribed or are currently taking Wegovy 1.7 mg or 2.4 mg should be able to continue with their treatment plan.
- Novo Nordisk has notified prescribers of the supply constraints and is advising to avoid starting new patients on Wegovy until the 2nd half of 2022, when supply is expected to resume.
- Alternative FDA-approved medications for chronic weight management such as [Saxenda® \(liraglutide\)](#), [Contrave® \(naltrexone/bupropion\)](#), [Qsymia® \(phentermine/topiramate\)](#), and [Xenical® \(orlistat\)](#) are available. Patients should speak with their healthcare provider to discuss treatment options.
- Although Wegovy and [Ozempic® \(semaglutide\)](#) both contain semaglutide, they are different products with different indications, dosages, and titration schedules. The products are **not** interchangeable.
 - Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2DM and to reduce the risk of major adverse cardiovascular events in adults with T2DM and established cardiovascular disease.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.